# Phenotype-Aligned Metabolomics Identifies Plasma Arginine as a Candidate Predictor of Delayed Cerebral Ischemia after Aneurysmal Subarachnoid Hemorrhage

**Authors:** Krzysztof Urbanowicz, Karol Wiśniewski, Mikołaj Opiełka, Michał Bieńkowski, Marta Popęda, Oliwier Krajewski, Ernest J. Bobeff, Karol Zaczkowski, Bartosz Szmyd, Dariusz J. Jaskólski, Ryszard T. Smoleński

PMC · DOI: 10.1007/s12975-026-01421-0 · Translational Stroke Research · 2026-03-25

## TL;DR

Plasma arginine levels 24-48 hours before DCI onset could predict delayed cerebral ischemia in subarachnoid hemorrhage patients.

## Contribution

Identifies plasma arginine as a novel candidate biomarker for predicting DCI with a specific pre-event detection window.

## Key findings

- Arginine was the only FDR-significant metabolite 24–48 hours before DCI onset.
- Arginine levels predicted DCI better than radiographic scores, with AUC of 0.808.
- Combining arginine with radiographic scores improved prediction to AUC 0.856.

## Abstract

Delayed cerebral ischemia (DCI) affects approximately 30% of aneurysmal subarachnoid hemorrhage (aSAH) survivors and is a leading cause of morbidity and mortality post-aSAH. Current risk assessment relies on radiographic severity scores that stratify populations based on hemorrhage characteristics but cannot predict DCI onset for individual patients. No plasma-based biomarkers for DCI prediction currently exist. We used liquid chromatography – mass spectrometry to perform plasma metabolomics in 60 aSAH patients (50% female, 30 DCI, 30 No-DCI) with longitudinal sampling until 7 days post-aSAH. Samples were retrospectively aligned to individual DCI onset times per patient, isolating 24–48 h and 48–72 h pre-event windows. Arginine emerged as the sole FDR-significant metabolite 24–48 h before DCI (q = 0.022, 39% depletion) and ranked #1 of 2,022 metabolites across three statistical methods (Student’s t-test, Welch’s t-test, Mann-Whitney U test, p = 10⁻⁵ to 10⁻⁴). Zero metabolites achieved FDR significance at 48–72 h, confirming temporal specificity. Independent logistic regression validated predictive performance (odds ratio 0.22, p = 0.001, AUC 0.808, 95% CI: 0.647–0.945), outperforming modified Fisher radiographic score (AUC 0.718, 95% CI: 0.593–0.830). The combination model of arginine and modified Fisher score performed best with AUC 0.856 (95% CI: 0.733–0.955), with arginine as the dominant factor. Mechanistic investigation revealed FDR-significant depletion of arginine/ornithine (q = 0.011) and glutamine/glutamate ratios (q = 0.011), consistent with increased arginase activity competing with nitric oxide synthesis. Plasma arginine represents a candidate single-molecule biomarker for DCI with a clinically actionable pre-event detection window, pending prospective validation. Temporal alignment to individual DCI onsets enabled detection of pre-event metabolic changes 24–48 h before symptom onset.

The online version contains supplementary material available at 10.1007/s12975-026-01421-0.

## Linked entities

- **Chemicals:** arginine (PubChem CID 232), ornithine (PubChem CID 389), glutamine (PubChem CID 738), glutamate (PubChem CID 611)

## Full-text entities

- **Genes:** ARG1 (arginase 1) [NCBI Gene 383], NOS2 (nitric oxide synthase 2) [NCBI Gene 4843] {aka HEP-NOS, INOS, NOS, NOS2A}, ECI1 (enoyl-CoA delta isomerase 1) [NCBI Gene 1632] {aka DCI}, NOS3 (nitric oxide synthase 3) [NCBI Gene 4846] {aka EC-NOS, ECNOS, MYMY8, NOSIII, cNOS, eNOS}, POSTN (periostin) [NCBI Gene 10631] {aka OSF-2, OSF2, PDLPOSTN, PN}, LGALS3 (galectin 3) [NCBI Gene 3958] {aka CBP35, GAL3, GALBP, GALIG, L31, LGALS2}, CSF2 (colony stimulating factor 2) [NCBI Gene 1437] {aka CSF, GMCSF}, SPP1 (secreted phosphoprotein 1) [NCBI Gene 6696] {aka BNSP, BSPI, ETA-1, OPN}
- **Diseases:** neurological deficits (MESH:D009461), UHPLC (MESH:D008228), pulmonary hypertension (MESH:D006976), urea cycle disorders (MESH:D056806), inflammatory (MESH:D007249), consciousness (MESH:D003244), thalassemia (MESH:D013789), Coma (MESH:D003128), ischemic injury (MESH:D017202), metabolic disease (MESH:D008659), arginase deficiency (MESH:D020162), Cerebral Ischemia (MESH:D002545), shock (MESH:D012769), vascular dysfunction (MESH:D002561), hemolysis (MESH:D006461), sickle cell anemia (MESH:D000755), acute lung injury (MESH:D055371), sepsis (MESH:D018805), ACN (MESH:D016518), critical (MESH:D016638), Aneurysmal Subarachnoid Hemorrhage (MESH:D013345), hemorrhage (MESH:D006470), aneurysm (MESH:D000783), renal dysfunction (MESH:D007674), death (MESH:D003643), CVS (MESH:D020301)
- **Chemicals:** Dimethylarginine (MESH:C487735), formic acid (MESH:C030544), water (MESH:D014867), reactive oxygen species (MESH:D017382), Ornithine (MESH:D009952), acetonitrile (MESH:C032159), SDMA (MESH:C024917), Citrulline (MESH:D002956), amino acid (MESH:D000596), methanol (MESH:D000432), Glutamic acid (MESH:D018698), Arg (MESH:D001120), ADMA (MESH:C018524), EDTA (MESH:D004492), MeOH (-), NO (MESH:D009569), Gln (MESH:D005973)
- **Species:** Homo sapiens (human, species) [taxon 9606]
- **Mutations:** glutamine/glutamate, glutamine-arginine, Gln/Glu

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC13013107/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13013107/full.md

---
Source: https://tomesphere.com/paper/PMC13013107